“This second vaccine holds real potential to close the huge demand-and-supply gap,” said
WHO's regional director for Africa, Matshidiso Moeti.“Delivered to scale and rolled out …

The World Health Organization has recommended widespread use of the RTS, S malaria
vaccine among children in sub-Saharan Africa and other areas with moderate to high …

A candidate vaccine against malaria has been shown to almost halve the number of malaria
cases in young children but only to reduce cases by a quarter in infants. The effectiveness of …

A vaccine candidate for malaria has become the first to meet the World Health
Organization's 75% efficacy target, after a trial in 450 children reported 77% efficacy. 1 The …

Manufactured by the Serum Institute of India, the R21/Matrix-M malaria vaccine contains the
circumsporozoite protein, secreted by the malaria parasite, fused to hepatitis B surface …

The efficacy of the vaccine RTS, S/AS01 in infants aged 6-12 weeks against clinical and
severe malaria was 31% and 37%, respectively, found the study, published in the New …

Throughout the covid-19 pandemic, global health scientists and professionals worried not
only about this new and emerging viral infection but also about a potential diversion of …

A phase III trial showed that the RTS, S vaccine, which acts against Plasmodium falciparum,
had an efficacy of around 30%. 1 The vaccine, which is most effective in children aged …

The initial results of the phase III clinical trial for RTS, S—currently the leading malaria
vaccine candidate—were recently announced, 1 amid international media coverage …

WHO’s rollout of malaria vaccine in Africa: can safety questions be answered after only 24
months? Page 1 WHO’s rollout of malaria vaccine in Africa: can safety questions be …